http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03016487-A3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1cd4a5a6815d08bca2b89bba83f9134d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a835ca70c6f82aac7dfa756fab802315 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-06 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-72 |
filingDate | 2002-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3ef68e265c753f9378c44ac250b6082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3bc071757edd90736646fc75b1ce493 |
publicationDate | 2003-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-03016487-A3 |
titleOfInvention | Mammalian relaxin receptors |
abstract | High affinity relaxin receptors, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. These proteins, herein termed LGR7 and LGR8, are orphan leucine-repeat-containing, G protein-coupled receptors. These receptors have a wide and a unique tissue expression pattern. The receptors, particularly soluble fragments thereof, are useful as therapeutic agents capable of inhibiting the action of relaxin and InsL3. The receptors and fragments thereof also find use in the screening and design of relaxin agonists and antagonists. Conditions treatable with relaxin agonists or antagonists include prevention or induction of labor, treatment of endometriosis, treatment of skin conditions such as scleroderma that require collagen or extracellular matrix remodelling. Additionally, relaxin has been implicated in the dilation of blood vessels' smooth muscle cells directly and through release of nitric oxide and atrial natriuretic peptide. Relaxin has also been used in the treatment of severe chronic pain, particularly pain arising from stretching, swelling, or dislocation of tissues. |
priorityDate | 2001-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.